Phase I randomized dose-ascending placebo-controlled trials of ferroquine - a candidate anti-malarial drug - in adults with asymptomatic Plasmodium falciparum infection

Table 4 Frequency of the most common adverse events during the multiple dose study

System organ class	Preferred term	Multiple Dose Study
		Placebo	Ferroquine
		(N = 7)	400 mg (N = 6)	600 mg (N = 6)	800 mg (N = 6)	1000 mg (N = 1)
Any class	Any TEAE	6 (86)	6 (100)	6 (100)	6 (100)	1 (100)
Gastrointestinal disorders	Any TEAE	4 (57)	3 (50)	4 (67)	5 (83)	1 (100)
	Abdominal pain	3 (43)	1 (17)	1 (17)	2 (33)	1 (100)
	Diarrhoea	0	0	0	2 (33)	0
	Nausea	1 (14)	2 (33)	2 (33)	3 (50)	0
	Toothache	1 (14)	1 (17)	0	2 (33)	0
	Vomiting	0	1 (17)	2 (33)	1 (17)	1 (100)
system disorders	Any TEAE	1 (14)	1 (17)	3 (50)	1 (17)	0
	Dizziness	0	0	1 (17)	0	0
	Headache	1 (14)	1 (17)	2 (33)	1 (17)	0

NOTE: N (%): count of patients (percentage per group); TEAE: treatment emergent adverse event

ISSN: 1475-2875